Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges
Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.
Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.